Neurizon Therapeutics Ltd., a clinical-stage biotech company, has announced promising preclinical results for their drug candidate NUZ-001 in a zebrafish model of Huntington's disease. The study demonstrated that NUZ-001 and its active metabolite, NUZ-001 Sulfone, exhibited significant neuroprotective effects. The treatment successfully prevented developmental and morphological abnormalities, protected against neuronal cell death, restored haemoglobin production, and rescued BDNF expression following the knockdown of the Htt protein. These findings underscore NUZ-001's potential as a platform therapy targeting core neurodegenerative mechanisms. Neurizon plans to initiate additional validation studies in mammalian models of Huntington's disease to further explore its therapeutic potential. These results were presented on June 16, 2025.